Should You Buy CytoDyn Shares Now?

The CytoDyn (OTC: CYDY) stock has been one of the many stocks that have emerged as ‘coronavirus plays’ this year. The company has come up with its product Vyrologix, which could be used to treat patients who are critically ill owing to COVID-19.

Should You Buy CytoDyn Shares Now?

This past Thursday the stock rocketed by as much as 9% after it emerged that a research manuscript about the product has been accepted by a leading journal. It is a significant development for the company and the market welcomed the news with great gusto.

The manuscript submission was made by Nicholas J. Agresti and it is going to be published in the Journal of Translational Autoimmunity. The research in question was based on the observations made by Agresti about four critically ill patients suffering from COVID 19 symptoms who had been administered with Vyrologix. The strong move in the CytoDyn could see the biotech being in focus among investors on Monday.

Should You Buy CytoDyn Shares Now?

Anthony Gonzales

Biotech, Tech, and Crypto reporterAnthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.